Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) rose 13.5% during mid-day trading on Monday . The company traded as high as $9.98 and last traded at $10.04. Approximately 329,360 shares changed hands during trading, a decline of 63% from the average daily volume of 893,914 shares. The stock had previously closed at $8.85.
Analysts Set New Price Targets
RGNX has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. The Goldman Sachs Group reduced their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research note on Tuesday, March 18th. Raymond James assumed coverage on shares of REGENXBIO in a research report on Friday, February 7th. They issued an "outperform" rating and a $27.00 price target for the company. Finally, Chardan Capital reissued a "buy" rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, REGENXBIO presently has an average rating of "Moderate Buy" and an average price target of $31.63.
Read Our Latest Stock Analysis on RGNX
REGENXBIO Stock Down 0.5%
The company has a market cap of $505.61 million, a price-to-earnings ratio of -2.00 and a beta of 1.11. The company's fifty day moving average price is $8.01 and its two-hundred day moving average price is $7.95.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Research analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.
Insider Transactions at REGENXBIO
In related news, Director Kenneth T. Mills sold 20,602 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director now owns 475,103 shares of the company's stock, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 12.79% of the company's stock.
Institutional Trading of REGENXBIO
Hedge funds and other institutional investors have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in shares of REGENXBIO in the first quarter valued at approximately $35,000. Brooklyn Investment Group increased its holdings in shares of REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,466 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Finally, Laurion Capital Management LP acquired a new stake in shares of REGENXBIO in the fourth quarter valued at approximately $79,000. Institutional investors and hedge funds own 88.08% of the company's stock.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.